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Abstract: Constitutive signaling through the phosphatidylinositol-3-kinase-Akt-mechanistic target of
rapamycin (PI3K-Akt-mTOR) pathway is present in acute myeloid leukemia (AML) cells. However,
AML is a heterogeneous disease, and we therefore investigated possible associations between cellular
metabolism and sensitivity to PI3K-Akt-mTOR pathway inhibitors. We performed non-targeted
metabolite profiling to compare the metabolome differences of primary human AML cells derived
from patients susceptible or resistant to the in vitro antiproliferative effects of mTOR and PI3K
inhibitors. In addition, the phosphorylation status of 18 proteins involved in PI3K-Akt-mTOR
signaling and the effect of the cyclooxygenase inhibitor indomethacin on their phosphorylation
status was investigated by flow cytometry. Strong antiproliferative effects by inhibitors were
observed only for a subset of patients. We compared the metabolite profiles for responders and
non-responders towards PI3K-mTOR inhibitors, and 627 metabolites could be detected. Of these
metabolites, 128 were annotated and 15 of the annotated metabolites differed significantly between
responders and non-responders, including metabolites involved in energy, amino acid, and lipid
metabolism. To conclude, leukemia cells that are susceptible or resistant to PI3K-Akt-mTOR inhibitors
differ in energy, amino acid, and arachidonic acid metabolism, and modulation of arachidonic acid
metabolism alters the activation of mTOR and its downstream mediators.
Keywords: acute myeloid leukemia; metabolism; mTOR; PI3K; phosphorylation
1. Introduction
Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by proliferating
myeloblasts in the bone marrow [1,2]. Abnormal constitutive signaling through intracellular pathways
is often observed in AML, including the phosphatidylinositol-3-kinase-Akt-mechanistic/mammalian
target of rapamycin (PI3K-Akt-mTOR) pathway that seems to be important both in normal and
leukemic hematopoiesis [3–5]. This pathway is important for regulation of proliferation, apoptosis,
differentiation, and metabolism [6,7].
Constitutive signaling through the PI3K-Akt-mTOR pathway is found in 50–80% of AML
patients and correlates with poor prognosis [4,8]. This abnormal signaling may be initiated by
various mechanisms, e.g., oncogenes or mutated receptor tyrosine kinases, cell adhesion molecules,
G-protein-coupled receptors, or other cytokine or hormonal receptors.
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When signaling is initiated in response to extracellular stimuli, scaffolding proteins are recruited
and bind to the regulatory subunit of PI3K. Sequentially, PI3K phosphorylates phosphatidylinositol
(4,5)-bisphosphate (PIP2) to generate phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which facilitates
recruitment and binding of proteins containing pleckstrin–homology domains, including Akt and
its upstream activator 3’phosphoinositide-dependent kinase 1 (PDK1) [9]. PDK1 phosphorylates
Akt at T308, leading to its partial activation. However, a subsequent phosphorylation at S473 is
required for full enzymatic activation of Akt [9,10], and this can be achieved by mTOR complex 2
(mTORC2) or DNA-dependent protein kinase (DNA-PK) [10,11]. The mTOR kinase is part of two
complexes, mTORC1 and mTORC2 with different biochemical structures and substrate specificity.
The interactions between Akt and mTORC1/2 are complex. Akt phosphorylates the inhibitor
of mTORC1 and proline-rich Akt-substrate-40 (PRAS40), preventing the suppression of mTORC1
signaling. Additionally, an Akt-driven inactivation of tuberous sclerosis complex (TSC) 1/2, leads
to activation of mTORC1 through Ras homolog enriched in brain (RHEB). mTORC1 is an important
regulator of cellular metabolism and protein synthesis through phosphorylation and activation of
both the S6 ribosomal protein kinase (S6PK) and the repressor of messenger RNA (mRNA) translation
initiation factor 4E-binding protein 1 (4EBP1) [6].
The PI3K-Akt-mTOR signaling pathway is one of the most frequently dysregulated pathways
in human malignancies, including AML [12,13]. Though PI3K-Akt-mTOR is rarely mutated in AML,
these patients harbor several mutations that may activate the pathway [12,14] and, hence, contribute
to chemoresistance [4,15]. Based on extensive experimental studies, this pathway has been regarded as
a possible therapeutic target in human AML [3,16]. However, despite this evidence, the initial clinical
studies suggest that the tested mTOR inhibitors have only a modest antileukemic effect [16]. However,
it should be emphasized that previous experimental studies also suggest that therapeutic targeting of
the PI3K-Akt-mTOR pathway will be effective only for a subset of patients [17], and pathway inhibition
may be more effective when using combined treatment strategies [18].
As discussed in a recent review, previous studies of resistance towards PI3K-Akt-mTOR inhibitors
have focused on the possible hyperactivation of upstream mediators through feedback loops (e.g., PI3K
and Akt) and compensatory activation of other pathways [16]. However, this cannot be the only
explanation because chemoresistance is also seen for inhibitors upstream to Akt [17]. Our present
study is to the best of our knowledge the first to suggest that metabolic alterations are a part of the
therapy-resistant AML cell phenotype, and the metabolic differences seem to involve pathways that
are involved in cellular energy and amino acid metabolism.
2. Results
2.1. Selection of Patients for the Metabolomics Comparison of Primary Human Acute Myeloid
Leukemia (AML) Cells
We investigated the antiproliferative effect of four PI3K-Akt-mTOR inhibitors on primary human
AML cell proliferation in the presence of exogenous cytokines [17]. The antiproliferative effects of
the inhibitors differed considerably between the 56 patient cell samples studied, and for a subset of
patients, even increased proliferation was seen in the presence of pathway inhibitors. In contrast,
these previous studies showed that pathway inhibitors had only minor effects on the spontaneous
stress-induced in vitro apoptosis that occurs during culture of primary human AML cells [19], and only
minor differences could then be detected between different patients [17]. Patient subsets could thus
be identified based solely on differences in our proliferation assay, i.e., these cells survived for 6 days
in the presence of the pathway inhibitors and could still proliferate and incorporate 3H-thymidine
during the period from day 6 to day 7 of the in vitro culture. This means that our subclassification was
based on the pharmacological effects on a cell subset within the hierarchically organized AML cell
population that were able to both survive and still be able to proliferate.
We also investigated the effects of pathway inhibitors on the in vitro proliferation of primary
human AML cells for a second and larger cohort including 76 additional consecutive patients; in these
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experiments, we only examined the effects of rapamycin and GDC-0941. The overall results are
presented in Figure 1. The studies of this second cohort confirmed that the antiproliferative effects
of PI3K-Akt-mTOR pathway inhibition varied among individual patients, and a variation of the
effect between the two drugs was observed. We also investigated the susceptibility to stress-induced
or spontaneous in vitro apoptosis for these 76 patients, but we could not observe any correlation
between this susceptibility to apoptosis and the antiproliferative effects of the two pathway inhibitors.
Taken together, our results from the two patient cohorts showed that neither the general regulation of
apoptosis, as reflected in the degree of spontaneous in vitro apoptosis, nor the viability of the AML cell
population after in vitro exposure to pathway inhibitors showed any significant association with the
variation in antiproliferative effects of pathway inhibitors that was detected in our proliferation assay.
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Figure 1. The effect of phosphatidylinositol-3-kinase-mechanistic target of rapamycin (PI3K-mTOR) 
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the proliferation of primary human AML cells cultured in the presence of the PI3K-inhibitor GDC-
0941 and the mTOR-inhibitor rapamycin. The results are presented as the ratio of proliferation, i.e., 
nuclear incorporation of 3H-thymidine in drug-exposed cells relative to the incorporation in 
corresponding drug-free control cultures. The patient cohort included 76 patients, but detectable 
proliferation was only seen for the 68 AML patients whose results are presented in the figure. Each 
line represents the results for one patient. The dashed line indicates a ratio of 1.0, i.e., no change in 
proliferation. 
The data presented in Figure 1 clearly illustrate that pathway inhibitors can increase AML cell 
proliferation for a subset of patients, whereas for other patients, a strong inhibition corresponding to 
more than 50% inhibition could be detected for different mediators. For further analysis of the 
possible association between metabolic characteristics and the antiproliferative effects of pathway 
inhibitors on primary human AML cells, we compared two contrasting groups of selected patients 
Figure 1. The effect of phosphatidylinositol-3-kinase-mechanistic target of rapamycin (PI3K-mTOR)
inhibitors on cytokine-dependent in vitro acute myeloid leukemia (AML) cell proliferation. Leukemic
cell proliferation was assayed as 3H-thymidine incorporation after six days of culture. We compared
the proliferation of primary human AML cells cultured in the presence of the PI3K-inhibitor GDC-0941
and the mTOR-inhibitor rapamycin. The results are presented as the ratio of proliferation, i.e., nuclear
incorporation of 3H-thymidine in drug-exposed cells relative to the incorporation in corresponding
drug-free control cultures. The patient cohort included 76 patients, but detectable proliferation was
only seen for the 68 AML patients whose results are presented in the figure. Each line represents the
results for one patient. The dashed line indicates a ratio of 1.0, i.e., no change in proliferation.
The data presented in Figure 1 clearly illustrate that pathway inhibitors can increase AML cell
proliferation for a subset of patients, whereas for other patients, a strong inhibition corresponding to
more than 50% inhibition could be detected for different mediator . For further analysis f the possible
association between metab lic haracteristics an the antip oliferative effects f pathway i hibitors on
primary human AML cells, we compared two contrasting groups of selected patients based on the
studies of the two patient cohorts. We then sele ted 15 patient samples with significantly d cre sed
proliferation after inhibition with both rapamycin and GDC-0941; these samples are referred to as
responders to the treatment. The other group included 15 patient samples showing no significant
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alteration of proliferation (corresponding to <10% inhibition) or even growth enhancement in the
presence of pathway inhibitors. These are referred to as non-responders to treatment.
2.2. Patient Samples with Different Drug Sensitivity towards PI3K-mTOR Inhibitors Also Differ in Energy,
Amino Acid and Arachidonic Acid Metabolism
Previous studies suggest that metabolic regulation of chronic myeloid leukemia cells is important
for their susceptibility towards targeted therapy with kinase inhibitors [20]. We compared the metabolic
profiles of the two contrasting patient groups that were sensitive and insensitive to PI3K-Akt-mTOR
inhibition in vitro. As described above, these groups were selected based on their susceptibility to the
antiproliferative effect of PI3K and mTOR inhibitors [17]. The metabolic analysis of the AML cells
detected a total of 627 metabolites, and 128 of these metabolites were annotated. A principal component
analysis was performed to illustrate the variance between the different sample groups. The responders
and non-responders showed a great overlap in the plot, though four of the non-responders clustered
separately from the rest (Figure 2). Thus, responders and non-responders could not be separated by an
analysis of the overall metabolic profile, and non-responder patients seem to be heterogeneous with
regard to their global metabolite profiles even though they show a similar resistance to PI3K-Akt-mTOR
pathway inhibition.
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Figure 2. Principal component analysis (PCA) comparing the metabolic profiles of responders and
non-responders to PI3K-mTOR inhibitors. The analysis was performed to generate an overview of the
metabolic variance among the entire set of samples. Prior to this analysis, primary AML cells from
30 patients were separated into two contrasting groups based on their susceptibility to the in vitro
antiproliferative effect of pathway inhibitors. The metabolic profiles for the primary AML cells derived
from patients being susceptible (15 responders; grey circle) or resistant (15 non-responders; black circle)
to PI3K-mTOR inhibitors were compared. The PCA depicts 71.2% (58.4 + 12.8% as indicated at the
X and Y axis) of all variances in the data set. A separation of four non-responders (indicated by the
asterisks *) from the rest of the sample was seen. Each circle represents the results for one patient.
Of the 627 detected metabolites, 23 metabolites differed significantly between the two contrasting
groups of responders and non-responders, and among these, 15 were annotated (Table 1). These
significantly altered metabolites are involved in energy (citric acid, isocitric acid, glutamine), amino acid
(proline, glutamine, taurine), and lipid metabolism (two phosphatidylinositols (PI), the arachidonic
acid metabolites 4,7,10,13-eicosatetraenoic acid, and 4,7,10,13,16-docosapentaenoic acid).
We did a metabolic pathway mapping based on the identified metabolites for further
characterization of differences between responders and non-responders based on the 80 top-ranked
metabolites. Purine metabolism (including the annotated metabolites glutamine, glutamic acid, glycine,
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and hypoxanthine) and Warburg effect (i.e., energy metabolism; including the annotated metabolites
NAD, glutamic acid, glutamine citric acid, and isocitric acid) were then the two highest-ranked
terms. This metabolic pathway mapping analysis further supports our conclusion that responders and
non-responders to PI3K-mTOR inhibitors show metabolic differences.
2.3. Responders and Non-Responders to PI3K-Akt-mTOR Inhibition Could Be Identified Based on
Metabolic Differences
No single metabolite could be used to identify responders and non-responders. However, a decision
tree analysis was performed showing that samples can be differentiated based on the levels of cysteinyl-
cysteine and threonic acid (Table 1). The patient subset sensitive to PI3K/mTOR inhibitors in vitro was then
characterized by low levels of both these metabolites (Figure 3). Cysteinyl-cysteine is a dipeptide composed
of two cysteine residues and an incomplete breakdown product of protein catabolism, whereas threonic
acid is probably derived from glycated proteins or degradation of ascorbic acid (Human Metabolome
Database). This additional and alternative analysis of our metabolomic data further illustrates that our
contrasting groups of responder and non-responder AML cells show metabolic differences.
Int. J. Mol. Sci. 2018, 19, x  5 of 18 
We did a metabolic pathway mapping based on the identified metabolites for further 
characterization of differences between responders and non-responders based on the 80 top-ranked 
metabolites. Purine metabolism (including the annotated metabolites glutamine, glutamic acid, 
glycine, and hypoxanthine) and Warburg effect (i.e., energy metabolism; including the annotated 
metabolites NAD, glutamic acid, glutamine citric acid, nd ocitri  acid) were then the two highest-
ranked terms. This metabolic pathway mapping analysis furth  supports our conclusion that 
r sponder  and n n-responders to PI3K-mTOR inhibitors show metab li  differences. 
2.3. Responders and Non-Responders to PI3K-Akt-mTOR Inhibition Could Be Identified Based on Metabolic 
Differences 
No single metabolite could be used to identify responders and non-responders. However, a 
decision tree analysis was performed showing that samples can be differentiated based on the levels 
of cysteinyl-cysteine and threonic acid (Table 1). The patient subset sensitive to PI3K/mTOR 
inhibitors in vitro was then characterized by low levels of both these metabolites (Figure 3). Cysteinyl-
cysteine is a dipeptide composed of two cysteine residues and an incomplete breakdown product of 
protein catabolism, whereas threonic acid is probably derived from glycated proteins or degradation 
of ascorbic acid (Human Metabolome Database). This additional and alternative analysis of our 
metabolomic data further illustrates that our contrasting groups of responder and non-responder 
AML cells show metabolic differences.  
 
Figure 3. A decision tree analysis of the metabolic differences between 15 responders and 15 non-
responders to PI3K-Akt-mTOR inhibition. The levels of two metabolites, cysteinyl-cysteine and 
threonic acid, allowed for discrimination between responders and non-responders. The 30 patients 
(see the upper box) were first classified into two subsets based on their cysteinyl-cysteine levels (≤ or 
>0.045). In the box with high cysteinyl-cysteine (>0.045; right box), there were 10 non-responders and 
1 responder. The 19 patients (14 responders and 5 non-responders) with low levels of cysteinyl-
cysteine (≤0.045; left box) were further subclassified into two subsets based on the level of threonic 
acid (≤ or >0.0145). Thirteen of the 14 responders with low levels of cysteinyl-cysteine also showed 
low levels of threonic acid (≤0.0145; left box). Whereas four of five non-responders among the 19 
patients with low levels of cysteinyl-cysteine showed high levels of threonic acid (>0.0145; right box). 
Approximately ninety percent of patients were then correctly classified as responders or non-
responders. 
Figure 3. A decision tree analysis of the metabolic differences between 15 responders and 15 non-
responders to PI3K-Akt-mTOR inhibition. The levels of two metabolites, cysteinyl-cysteine and
threonic acid, allowed for discrimination between responders and non-responders. The 30 patients
(see the upper box) were first classified into two subsets based on their cysteinyl-cysteine levels (≤ or
>0.045). In the box with high cysteinyl-cysteine (>0.045; right box), there were 10 non-responders and
1 responder. The 19 patients (14 responders and 5 non-responders) with low levels of cysteinyl-cysteine
(≤0.045; left box) were further subclassified into two subsets based on the level of threonic acid (≤ or
>0.0145). Thirteen of the 14 responders with low levels of cysteinyl-cysteine also showed low levels of
threonic acid (≤0.0145; left box). Whereas four of five non-responders among the 19 patients with low
levels of cysteinyl-cysteine showed high levels of threonic acid (>0.0145; right box). Approximately
ninety percent of patients were then correctly classified as responders or non-responders.
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Table 1. A description of annotated metabolites that differed significantly between the two patient groups and were sensitive (responders) or insensitive






↓Allose 0.037 −0.875 Sugar metabolism. Possibly involved in cell cycle regulation.
↓Citric acid 0.005 −1.262 Energy metabolism, citric acid cycle.
↓Cysteinyl-cysteine 0.006 −1.471 Dipeptide
↓Glutamine 0.029 −0.737 Non-essential amino acid, important for nucleic acid synthesis.Energy metabolism, conditionally essential during catabolic states.
↓Indoleacrylic acid 0.047 −0.426 Involved in tryptophan metabolism.
↓Isocitric acid 0.029 −0.698 Substrate of the citric acid cycle.
↑Phosphatidyl inositol (18:0/0:0) 0.040 0.765 Lipid metabolism, cell membrane constituents.
↑Phosphatidyl inositol
(15:1(9Z)/22:6(4Z,7Z,10Z,13Z16Z19Z)) 0.025 0.809 Lipid metabolism, cell membrane constituents.
↓Phosphonic acid (8:0/8:0) 0.009 −1.660 Lipid metabolism
↓Proline 0.046 −0.611 Non-essential amino acid, synthesized from glutamic acid and also other amino acids,energy metabolism.
↓Taurine 0.035 −1.0524 Sulfur amino acid not incorporated into protein; adults can synthesize taurine fromcysteine. Stabilizes cell membranes, regulates ion transport.
↓2-amino-4-hydroxy-propiophenone 0.021 −0.744 Lipid metabolism
↓4-phenyl-1,2,3-thiadiazole 0.041 −1.024 Inhibitor of cytochrome P450 enzymes that regulate arachidonic acid metabolism.
↓4,7,10,13-eicosatetraenoic acid 0.021 −0.983 Arachidonic acid metabolite, possibly influencing the leukotriene B4 (LTB4) pathway;expression of the LTB4 receptor (BLT1) may be altered in myeloid leukemia cells.
↓4,7,10,13,16-docosapentaenoic acid 0.042 −0.766
Fatty acid and arachidonic acid metabolism, an intermediate between eicosapentaenoic
acid and docosahexaenoic acid, precursor of prostanoids that are only formed from
docosapentaenoic acid.
* Responders versus non-responders were compared as the log2-ratio. The arrows to the left in the table indicate whether the mean metabolite levels were decreased (↓) or increased (↑) in
responder cells relative to the non-responder cells. The information in this table is based on PubChem and Human Metabolome databases.
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2.4. Modulation of Arachidonic Acid Metabolism Alters PI3K-Akt-mTOR Signaling
In a previous study, we used Western blot to analyze phosphorylation mediators downstream
of mTOR in a small group of patients treated with PI3K-mTOR inhibitors [17]. Even though these
results have to be interpreted with great care as few patients were studied, the observations suggested
that (i) patients differed considerably with respect to the degree of constitutive signaling through the
PI3K-Akt-mTOR pathway; and (ii) the heterogeneous antiproliferative effects of PI3K-mTOR inhibitors
seen among patients could not be explained by differences in constitutive pathway activation.
Arachidonic acid metabolism seems to be important for survival and proliferation of various
cells, including myeloid cells [21,22]. Arachidonic acid can be metabolized by cyclooxygenase,
lipoxygenase, or the cytochrome P450 pathways into a number of metabolites, referred to as eicosanoids.
These arachidonic acid derived eicosanoids belong to a complex family of lipid signaling mediators
that control many important cellular processes, including cell proliferation, apoptosis, and cell
metabolism [21,23]. Therefore, we wanted to investigate whether modulation of the balance between
the various pathways of arachidonic acid metabolism would influence PI3K-Akt-mTOR signaling in
primary human AML cells.
In these experiments, we modulated the balance of arachidonic acid metabolism by incubating
the cells with indomethacin (a nonselective cyclooxygenase 1/2 inhibitor), and we investigated the
effects of this inhibitor on PI3K-Akt-mTOR signaling in primary AML cells derived from five patients
showing constitutive signaling throughout this pathway. These five patients showed a wide variation
in constitutive pathway activation; this activation was also observed in previous Western blot analyses
of the downstream mTOR mediators P70SK6 and p4E-BP1 (see above) [17]. Thus, a variation in the
degree of constitutive pathway activation can be detected by both Western blot and phospho-flow,
and, therefore, we selected five patient samples with a constitutive, though wide variation of signaling.
The variation between these five patients was, in addition, reproduced/documented in independent
analysis of cells derived from separate freezing ampullas.
Using a flow cytometry technique, we explored the effects of indomethacin of the PI3K-Akt-mTOR
pathway (10 µg/mL, 15-min incubation) for cells incubated in medium alone (i.e., constitutive signaling)
and medium supplemented with insulin 10 µg/mL (Figures 4 and 5). Insulin was studied because
PI3K-Akt-mTOR is an important pathway downstream of the insulin receptor [24,25], and in vitro
studies have shown that insulin is an important growth factor for primary AML cells for a major
subset of patients [26]. When performing an unsupervised hierarchical clustering of the overall results,
we observed that the four combinations tested (medium alone± indomethacin, insulin± indomethacin)
for each individual patient sample generally clustered together; showing that differences in pathway
signaling between patients were maintained even in the presence of cyclooxygenase inhibition.
An indomethacin-induced decrease of mTOR pS2448, S6 pS235 pS236, and S6 pS244 was seen for
all patients in insulin-free and/or insulin-supplemented cultures, and for four of the five patients
a decrease was seen for Akt pS473 and S6 pS240 (Figure 4).
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Figure 4. In vitro phospho-signaling analysis of primary AML cells derived from five patients to
explore the effects of indomethacin on the PI3K-Akt-mTOR pathway. AML cells were incubated in
medium alone, in medium supplemented with 10 µg/mL of either indomethacin or insulin, and in
medium supplemented with the combination of insulin and indomethacin. Phosphorylation status of
nine mediators were examined. An indomethacin-induced decrease of mTOR pS2448, S6 pS235 pS236,
and S6 pS244 was seen for all patients in insulin-free and/or insulin-supplemented cultures, and a
decrease of S6 pS240 and Akt pS473 was seen for four of the five patients. The X-axis is a log-scale for
fluorescence intensity; the Y-axis indicates the number of cells.
Based on our current observations, we conclude that modulation of arachidonic acid metabolism
by exposure to indomethacin has only minor effects on the phosphorylation of certain mediators
in the PI3K-Akt-mTOR pathway; a similar conclusion can be made also for insulin. Only minor
effects were observed on the overall pathway activation profile compared with the observed wide
variation in constitutive pathway activation between different patients. Accordingly, our results in
Figure 5 illustrate that the wide variation between patients in constitutive pathway activation seems
to be maintained also after exposure of the leukemic cells to insulin, as well as after drug-induced
modulation of arachidonic acid metabolism, i.e., samples from an individual patient cluster together
whereas samples from insulin/indomethacin exposed cells do not cluster together.
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Figure 5. The effect of indomethacin on the activation of PI3K-Akt-mTOR signaling. We investigated
the effects of indomethacin on PI3K-Akt-mTOR signaling in primary AML cells derived from five
patients. For each sample, we tested AML cells incubated in medium alone, with only indomethacin
10 µg/mL, in medium supplemented with 10 µg/mL insulin, and with the combination of insulin
and indomethacin. Phosphorylation status of nine mediators were examined. Red indicates high and
blue indicates low phosphorylation/expression of the mediators. All combinations tested for each
patient sample also clustered together in the same subclusters for all patients. All values from the flow
cytometric analyses were calculated using fold change on the Inverse hyperbolic sine (Arcsinh) scale.
3. Discussion
The PI3K-Akt-mTOR signaling network shows constitutive activation in human AML [12].
However, previous experimental studies [17] suggest that the antileukemic effects of pathway inhibitors
differ between patients, and the aim of the present study was to further characterize this patient
heterogeneity with regard to constitutive PI3K-Akt-mTOR activation/signaling, pathway inhibition,
and metabolic regulation.
For younger patients receiving the most intensive chemotherapy, the overall long-term AML-free
survival is only 40–50%. However, the large group of patients above 70–75 years of age are not able to
receive this intensive therapy, and are therefore, treated with AML-stabilizing treatment [27]. Many of
these elderly patients, as well as younger unfit patients, have an expected survival of only 1–3 months.
Thus, new therapeutic strategies are needed both for younger as well as for elderly and unfit patients
who can only receive AML-stabilizing treatment; combination therapy including PI3K-Akt-mTOR
inhibitors may then be an alternative therapeutic strategy [3,16,18]. However, due to the short survival
of many elderly and unfit patients [28,29], they may get only one chance of antileukemic therapy
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because of the rapid disease progression if this first treatment fails. For this reason, pretreatment
identification of patients with high risk of resistant disease will be important. Our present study
suggests that metabolic characterization should be further explored as a possible strategy to identify
patients with a high risk of resistance to PI3K-Akt-mTOR inhibition, and such patients should then try
an alternative strategy as their initial treatment.
In vitro cultured hierarchically organized AML cell populations show spontaneous apoptosis during
the first 4–5 days of culture; for most patients, this is an extensive process [19]. Our previous study
showed that PI3K-mTOR inhibitors only have weak influence on this spontaneous or stress-induced
in vitro apoptosis, and the variation between patients is limited so that it cannot be used for subset
classification [17]. However, a wide variation between patients can be detected when using our
3H-thymidine incorporation assay after six days of in vitro culture, i.e., an analysis of the AML cell
minority that has been able to survive the initial six days of in vitro culture and still are able to
proliferate. Inhibitors of the PI3K-Akt-mTOR pathway were added at the start of the cultures. Our patient
classification reflects a combined effect of pathway inhibitors on both survival and proliferation, i.e., the
presence of the drug during the initial six days characterized by spontaneous in vitro apoptosis and the
ability of the remaining viable cells to still show cytokine-dependent proliferation in the presence of the
pathway inhibitors when 3H-thymidine incorporation is assayed from day six to seven of in vitro culture.
We investigated the effect of insulin on phosphorylation of the PI3K-Akt-mTOR-pathway as this
pathway is important for insulin signaling [24,25], and insulin is also an important growth factor for
in vitro cultured primary human AML cells for a large subset of patients [26]. Our present studies
showed that insulin altered the activation/phosphorylation of several mediators; however, the effects
were minor and differed between patients. Also, the wide variation in PI3K-Akt-mTOR pathway
activation between patients was maintained in the presence of insulin (i.e., the samples exposed to
insulin did not cluster together with each other but rather together with the corresponding insulin-free
control (Figures 4 and 5)).
Even though constitutive activation of PI3K-Akt-mTOR signaling in the enriched leukemic cells is
seen for most AML patients, resistance to the antiproliferative effect of pathway inhibitors is relatively
common. In our present study, we show that resistant patient-derived leukemia cells differ with
regard to their metabolomic profile, including the metabolites involved in amino acid and arachidonic
acid metabolism. Similar abnormalities are also associated with chemoresistance in other myeloid
malignancies [30].
Arachidonic acid metabolism is important for survival and proliferation of hematopoietic
cells [21,23,31–33] and several of its metabolites can influence activation/signaling through
the PI3K-Akt-mTOR pathway, e.g., pathway-activating prostaglandins and eicosatetraenoic acid
derivatives [31–35]. Our comparison of the metabolite profiles of cell samples representing either
responders or non-responders to PI3K-Akt-mTOR inhibition supports the hypothesis that arachidonic
acid metabolism is important with regard to susceptibility to these inhibitors. This hypothesis was
also supported by our observed effects of modulated arachidonic acid metabolism by indomethacin
on mediator phosphorylation, and previous studies in both human chronic myeloid leukemia and in
animal models of leukemic stem cells indicating that arachidonic acid metabolism is important for
both leukemogenesis and chemosensitivity [20,36].
For other cell types, there are functional links between redox balance, purine metabolism,
NADH, proline, and glutamine metabolism, and the citric acid cycle [37–41]. Even though few
studies of myeloid cells are available, observations in other cell types suggest links between such
metabolic steps and PI3K-Akt-mTOR signaling. Firstly, arachidonic acid metabolites can function
as regulators of the PI3K-Akt-mTOR pathway [21,23,42,43], and our present results suggest that
this may also be true in human AML. Secondly, there are links between PI3K-Akt-mTOR signaling
via free oxygen radicals/redox homeostasis to the NAD/NADH/proline/glutamine/glutamate
system [44,45]. Thirdly, proline and glutamine are interconvertible, and glutamine is an important
substrate for the energy metabolism in many malignant cells; a link between arachidonic acid and
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energy metabolism/the citric acid cycle is therefore possible [37,39]. Finally, both arachidonic acid
metabolism and PI3K-Akt-mTOR signaling are important for regulation of the peroxisome proliferator
activated receptors, a group of transcription factors [21,40]. However, additional studies are needed to
clarify the possible contributions of these various steps in human AML.
Previous experimental studies suggest that altered proline metabolism can be important for the
development of cancer chemoresistance, and proline oxidase has been suggested as a possible target
in cancer treatment [37,39,41,46]. Our present study suggests that proline/glutamine metabolism
may also contribute to resistance of PI3K-mTOR inhibitors in human AML. Our observation of
increased levels of eicosatetraenoic acid and docosapentaenoic acid indicates that arachidonic acid
may be one of these interacting factors. However, an alternative explanation could be that effects on
proline/glutamine only reflect differences in energy metabolisms, and differences in arachidonic acid
metabolites may reflect the altered energy/lipid metabolism. This is further supported by previous
studies showing that arachidonic acid metabolism is important in murine leukemogenesis and for
chemoresistance in human chronic myeloid leukemia [20,36]. The PI3K-Akt-mTOR pathway may
represent a link between these two systems through the effect of arachidonic acid metabolites on this
pathway and the regulatory effect of mTOR on proline oxidase.
The role of arachidonic acid and its metabolites in normal and malignant hematopoiesis has
been reviewed previously [21]. Increased expression of lipoxygenase enzymes has been detected in
malignant myeloid cells, and products from this pathway of arachidonic acid metabolism often seem
to mediate growth-enhancing and antiapoptotic effects. Our present observations of increased levels
of eicosanoids in cells that are resistant to PI3K-Akt-mTOR inhibitors suggest that these metabolites
may have such a role in human AML. Furthermore, the effect of arachidonic acid itself seems to differ
between cell lines, but proapoptotic effects have been described. Finally, a previous study of primary
human AML cells showed that even low levels of indomethacin could reduce the AML cell levels of
prostaglandin E2, and in their model PGE2, could enhance both the spontaneous proliferation as well
as Toll like receptor mediated growth enhancement of primary human AML cells [47].
4. Materials and Methods
4.1. AML Patients
The study was approved by the Regional Ethics Committee (REK) (REK III 060.02, 10 June 2002;
REK Vest 215.03, 12 March 04; REK III 231.06, 15 March 2007; REK Vest 2013/634, 19 March 2013; REK
Vest 2015/1410, 19 June 2015), The Norwegian Data Protection Authority 02/1118-5, 22 October 2002,
and The Norwegian Ministry of Health 03/05340 HRA/ASD, 16 February 2004. All AML cell samples
were collected after written informed consent.
The clinical and biological characteristics of those 30 patients included in the metabolic studies
are summarized in Table 2. All patients had a high number and/or percentage of peripheral blood
blasts; leukemic peripheral blood mononuclear cells could, therefore, be isolated by density gradient
separation alone (Lymphoprep, Axis-Shield, Oslo, Norway) and generally contained at least 95%
leukemic blasts. The contaminating cells were small lymphocytes. These enriched AML cells were
stored in liquid nitrogen until used in the experiments [48]. All the 15 responder patients selected
for metabolic profiling had a strong inhibition (i.e., >50% inhibition) of cytokine-dependent AML
cell proliferation by both PI3K and mTOR inhibitors, whereas PI3K and mTOR inhibition either
increased the proliferation or had a weak antiproliferative effect corresponding to <10% inhibition for
the 15 non-responders.
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Malignancy or Chemotherapy FAB CD34
Karyotype
Flt3 Mutation NPM-1 Mutation
Abnormality Classification
Responders
1 F 45 Chemotherapy M4 Negative Normal Normal wt ins
2 F 63 M4 Positive Normal Normal ITD wt
3 M 72 M5 Negative Normal Normal wt ins
4 M 29 Relapse M4 Positive Normal Normal ITD ins
5 F 80 M2 Positive Complex Adverse wt wt
6 F 36 M4 Positive Normal Normal wt nt
7 F 75 M1 Positive nt ITD wt
8 M 71 Relapse M2 Negative Normal Normal G835
9 M 35 M2 Positive Normal Normal wt wt
10 M 72 Myelodysplastic syndrome M1 Positive Complex Adverse wt
11 F 64 Chemotherapy M2 Negative Normal Normal ITD ins
12 F 59 Chemotherapy M5 Negative Normal Normal ITD ins
13 M 58 M5 Positive Normal Normal wt wt
14 F 59 Chemotherapy M4 Negative Normal Normal ITD ins
15 F 75 M4 Positive Normal Normal ITD wt
Non-responders
16 F 29 Chemotherapy M5 Positive Normal Normal ITD+Asp835 wt
17 M 24 M2 Positive Multiple Adverse nt wt
18 F 82 M4 Positive Normal Normal ITD wt
19 F 77 M1 Negative nt nt ins
20 M 84 M1 Positive Multiple Adverse wt wt
21 M 53 M0 Positive 13 Intermediate wt wt
22 M 65 M5 Negative Normal Normal ITD ins
23 F 46 M1 Positive inv(16) Favorable wt wt
24 F 70 M4 Negative nt wt ins
25 M 33 Chemotherapy M1 Positive Normal Normal wt wt
26 F 77 M1 Positive nt nt wt
27 M 76 M0 Positive Normal Normal wt wt
28 M 60 M4 Positive Normal Normal ITD wt
29 M 36 M5 Positive +8, +22, inv(16) Favorable ITD wt
30 F 67 M5 Negative t(9,11), +19 Intermediate wt wt
The table shows the gender (M, male; F, female) and age (years) of the individual patients at diagnosis. The FAB classification was used to classify morphological and/or histochemical
signs of differentiation. Cytogenetic abnormalities were classified according to the medical research council (MRC) criteria. The detection of Fms like tyrosine kinase 3 (Flt3) (ITD, internal
tandem duplications) or nucleophosmin (NPM)-1 insertions (ins) is also indicated in the table. Complex karyotype means at least three abnormalities [1]. FAB: The French-American-British
(FAB) classification system; nt: not tested; wt: wild type.
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4.2. Drugs
Drugs used in this study included the mTOR inhibitor rapamycin (LC Laboratories, Woburn, MA,
USA), the PI3K class I specific inhibitor GDC-0941 (Axon Medchem BV, Groningen, The Netherlands),
human insulin (Sigma-Aldrich, St. Louis, MO, USA), and the nonselective cyclooxygenase 1/2 inhibitor
indomethacin (Sigma-Aldrich; dissolved in dimethyl sulfoxide (DMSO)). Stock solutions were sterile
filtered and stored at −20 ◦C until used in experiments, thawed only once, and diluted with their
respective solvents to obtain the desired final concentrations.
Indomethacin (Sigma-Aldrich) was tested at a final concentration of 10 µg/mL (corresponding to
28 µM). Previous studies in human as well as murine AML cells often used indomethacin concentrations
in the range of 10–50 µM (3.6–18 µg/mL) [49–51], and the conventional cyclooxygenase-blocking
concentration of indomethacin is considered to be 10–20 µM (for original reference see [50]). However,
even indomethacin concentrations as low as 1 µM (0.4 µg/mL) will decrease the in vitro prostaglandin
production by primary human acute leukemia cells [47]. Our use of indomethacin 10 µg/mL was
based on these previous studies. Finally, in pilot experiments we investigated pharmacological effects
after incubation for 7, 10, 15, 30, and 45 min before analyzing the PI3K-Akt-mTOR pathway activation.
We decided to incubate cells with the drugs for 15 min because additional effects could not be detected
when using longer incubations.
4.3. Analysis of PI3K-Akt-mTOR Activation
Flow cytometry was used to examine the basal expression of 18 mediators in the PI3K-Akt-mTOR
pathway/network in the AML cells. Cryopreserved and thawed primary leukemic cells were incubated
for 20 min in RPMI-1640 (Sigma-Aldrich) before being directly fixed in 1.5% paraformaldehyde (PFA)
and permeabilized with 100% methanol. The cells were subsequently rehydrated by adding 2 mL
phosphate-buffered saline (PBS), gently re-suspended, and then centrifuged. The cell pellet was washed
twice with 2 mL PBS and resuspended in 150 µL PBS supplemented with 0.1% bovine serum albumin
(BSA) (Sigma-Aldrich). Washed cells were blocked with immunoglobulin (Octagam; Octapharma,
Jessheim, Norway) and 1% BSA, and then split evenly into nineteen new tubes (1× 105 cells per sample)
before staining. All staining panels included the same live/dead discriminator, either FITC or Alexa
Fluor® 647 Mouse anti-Cleaved PARP (Asp214); an unstained sample was also included. Three directly
conjugated dyes were used: (i) Alexa Fluor® 647 was used for PTEN, PDPK1 pS241, PKCα, PKCα
pT497, Akt pS473, 4EBP1 pT36 pT45, elF4E pS209, S6 pS244, and mTOR; (ii) phycoerythrin (PE) for
Akt total, Akt pT308, mTOR pS2448, and S6 pS240; and (iii) V450 for S6 pS235 pS236. Antibodies were
purchased from BD Pharmingen (Franklin Lakes, NJ, USA), except for anti-mTOR that was purchased
from Cell Signal Technology (Danvers, MA, USA). Four of the antibodies were unconjugated (anti
Raptor, Tuberin, FKBP38, and RHEB; all from Abcam; Cambridge, UK) and required secondary
antibody-conjugated Alexa Fluor® 647 (BD Pharmingen). Together these mediators represent the main
steps in the PI3K-Akt-mTOR pathway and they were selected to provide an extended phosphorylation
profile of this pathway. Finally, in our pharmacological studies, AML cells were incubated with human
insulin 10 µg/mL (Sigma-Aldrich) and/or indomethacin 10 µg/mL (Sigma-Aldrich; dissolved in
DMSO); final concentration in the medium 0.5%) or a DMSO control solution for 15 min before flow
cytometric analysis as described above. Flow cytometry analysis was acquired on a BD FACS Verse
8-color flow cytometer (BD Biosciences, San Jose, CA, USA) and data analysis performed using FlowJo
10.0.7 software (Tree Star, Inc., Ashland, OR, USA).
4.4. Analysis of Cytokine-Dependent Proliferation in Presence of PI3K-mTOR Inhibitors
As described in detail previously [52,53]; AML cells (5 × 104 cells/well) were cultured in
flat-bottomed microtiter plates (150 µL/well) in Stem Span SFEMTM serum-free medium (Stem Cell
Technologies; Vancouver, BC, Canada) alone or in medium supplemented with granulocyte-macrophage
colony-stimulation factor (GM-CSF), stem cell factor (SCF) and Fms like tyrosine kinase 3 ligand
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(Flt3L) [54]. All cytokines were purchased from Peprotech (Rocky Hill, NJ, USA) and used at 20 ng/mL.
All drugs were added on the first day of culture, whereas 37 kBq/well of 3H-thymidine (Perkin Elmer;
Waltham, MA, USA) was added after 6 days, and nuclear incorporation was assayed after seven days
of culture. The mTOR inhibitor rapamycin and the PI3K inhibitor GDC-0941 were added at a final
concentration of 100 nM on the first day of culture [55].
4.5. Metabolomic Analysis
The metabolomic analyses and sample preparations were performed by Metabolomic Discoveries
GmbH (Potsdam, Germany) [56]. Briefly, non-targeted metabolite profiling of cells included analyses by
gas chromatography/mass spectrometry (GC-MS) and Liquid Chromatography Quadrupole-Time of
Flight (LC-QTOF)/MS; metabolites could then be analyzed in the range of 50–1700 Da with an accuracy
up to 1–2 ppm and a resolution of mass/∆mass = 40,000. Metabolites measured in the LC were
annotated according to their accurate mass and subsequent sum formula prediction. Metabolite profiles
were explored by the platforms of Metabolomic Discoveries and Small Molecule Pathway Database
(BioVariance, Munich, Germany). The lists of the 627 detected and the 128 annotated metabolites
are presented in the Supplementary Materials presenting the identity/accurate mass@retention time,
the p-value, and responder/non-responder ratio.
4.6. Bioinformatical and Statistical Analyses
Bioinformatic analyses were performed using the J-Express 2012 software (MolMine AS, Bergen,
Norway). For hierarchical clustering analysis, all values from cytometric analyses were calculated using
fold change on the Inverse hyperbolic sine (Arcsinh) scale. The median signal for each phospho-protein
was used as reference value for the calculation of basal phosphorylation. Complete linkage and Squared
Euclidean correlation were used as linkage method and distance measurement, respectively. Statistical
analyses were performed using the IBM Statistical Package for the Social Sciences (SPSS) version 23
(Chicago, IL, USA), and p-values < 0.05 were regarded as statistically significant.
5. Conclusions
Despite the metabolic heterogeneity of the non-responders to PI3K-Akt-mTOR inhibitors, there
are distinct metabolic differences between responders and non-responders. Our present results are
consistent with the hypothesis that differences in arachidonic acid metabolism together with differences
in proline and/or energy metabolism are associated with differences in susceptibility to pathway
inhibitors. The possible importance of such differences should be considered when planning or
analyzing future clinical studies with PI3K-Akt-mTOR inhibitors and when designing combination
therapy for various AML patient subsets [57].
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/2/
382/s1.
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Abbreviations
4EBP1 Translation initiation factor 4E-binding protein 1
AML Acute myeloid leukemia
DMSO Dimethyl sulfoxide
DNA-PK DNA-dependent protein kinase
FAB The French-American-British () classification system
Flt3 Fms like tyrosine kinase 3
Flt3L Flt3 ligand
GC-MS Gas chromatography-mass spectrometry
GM-CSF Granulocyte-macrophage colony-stimulation factor
ins Insertions
ITD Internal tandem duplications
LC-QTOF/MS Liquid Chromatography Quadrupole-Time of Flight MS
mRNA Messenger RNA




PCA Principal component analysis






RHEB Ras homolog enriched in brain
S6PK S6 ribosomal protein kinase
SCF Stem cell factor
SPSS Statistical Package for the Social Sciences
TSC Tuberous sclerosis complex
elF4E pS209 eukaryotic translation Initiation Factor 4E
PKCα Protein kinase C α
PTEN Phosphatase and tensin homolog
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